Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360447 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1094678 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL8359816 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL8356129 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1109744 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1094676 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1109745 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1109740 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL191429 | 0.98 | ACMSD (0.49) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL8380044 | 0.98 | ACMSD (0.49) | ACMSDELANETDP1PTGS2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153836-B2 | Silsesquioxane compound mixture, hydrolyzable silane compound, making methods, resist composition, patterning process, and substrate processing | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20080311514-A1 | SILSESQUIOXANE COMPOUND MIXTURE, HYDROLYZABLE SILANE COMPOUND, MAKING METHODS, RESIST COMPOSITION, PATTERNING PROCESS, AND SUBSTRATE PROCESSING | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311514-A1 | SILSESQUIOXANE COMPOUND MIXTURE, HYDROLYZABLE SILANE COMPOUND, MAKING METHODS, RESIST COMPOSITION, PATTERNING PROCESS, AND SUBSTRATE PROCESSING | STS, LSS, SRMS | ACMSD 348/4885ELANE 99/4885TDP1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.